A Novel Investigational PD-1 x VEGF Bispecific Antibody for Patients With Cancer
Explore our clinical trials, which are evaluating a study
medicine, [PF-08634404], for different types of cancer.
This page is intended for healthcare professionals only.
A Novel Investigational PD-1 x VEGF Bispecific Antibody for Patients With Cancer
Explore our clinical trials, which are evaluating a study medicine, [PF-08634404], for different types of cancer.
This page is intended for healthcare professionals only.
About the study medicine
Pfizer is investigating a study medicine, [PF-08634404], which is a bispecific antibody that was designed to target both PD-1 and VEGF to potentially block immune checkpoints and inhibit angiogenesis. This dual mechanism has the potential to achieve tumor immunosurveillance, while disrupting vascular support for tumor progression, compared with blocking either target alone in patients with solid tumors.
The study medicine is currently being studied in various cancer types, including lung, colorectal, urothelial, renal, and hepatocellular carcinomas, as well as other advanced solid tumors.
Our clinical trials
Explore Pfizer’s novel investigational PD-1 x VEGF bispecific antibody program, which is a series of clinical trials evaluating a bispecific antibody that was designed to target both PD-1 and VEGF.
[Study name/C6461001]: Investigating a bispecific antibody for locally advanced or metastatic non-small cell lung cancer
[Study name/C6461003]: Investigating a bispecific antibody for metastatic colorectal cancer
A Phase 3 clinical trial evaluating [PF-08634404] or [bevacizumab] combined with chemotherapy in your patients with metastatic colorectal cancer who have not received prior systemic treatment for metastatic disease.
[Study name/C6461004]: Investigating a bispecific antibody for extensive-stage small cell lung cancer
A Phase 2/3 clinical trial of [PF-08634404] combined with chemotherapy in extensive-stage small cell lung cancer for your patients who have not received prior systemic therapy for ES-SCLC.
[Study name/C6461006]: Investigating a bispecific antibody for locally advanced or metastatic urothelial cancer
A Phase 1b/2 clinical trial of [PF-08634404] as monotherapy or in combination with [enfortumab vedotin] for your patients with unresectable, locally advanced, or metastatic urothelial cancer. The clinical trial includes participants previously treated and those previously untreated for locally advanced or metastatic urothelial cancer.
[Study name/C6461008]: Investigating a bispecific antibody for locally advanced or metastatic renal cell carcinoma
A Phase 1b/2 clinical trial of [PF-08634404] as monotherapy and combination therapy with [ipilimumab] or [axitinib] for your patients with locally advanced or metastatic renal cell carcinoma who have received no previous systemic therapy for RCC.
[Study name/C6461013]: Investigating a bispecific antibody for locally advanced or metastatic hepatocellular carcinoma
A Phase 1b/2 clinical trial of [PF-08634404] as monotherapy and in combination with [ipilimumab] for your patients with unresectable, locally advanced, or metastatic hepatocellular carcinoma.
[Study name/C6461020]: Investigating a bispecific antibody for advanced solid tumors
A Phase 1b/2 clinical trial of [PF-08634404] in combination with different anticancer agents in your patients with advanced solid tumors. The clinical trial currently includes combinations of [PF-08634404] with different antibody drug conjugates (ADCs) in treatment-naive patients with locally advanced or metastatic non-small cell lung cancer without actionable genomic alterations.
